Skip to Search
Skip to Navigation
Skip to Main Content
Skip to Footer
About Us
Life Sciences Publications
Our Medicines
Topic Articles
Topic Discussions
Login
Google Translate
Select language
English
French
Spanish
Login
Username
*
Password
*
Staff Login
×
Google Translate
Select language
English
French
Spanish
Login
Menu
Site Search
Search Options
Resources
Everything
Advanced Search
Uptodate
All
Title Search
Author
Patients & Caregivers
Healthcare Providers
Researchers & Partners
Investors
menu
About Us
Life Sciences Publications
Our Medicines
Topic Articles
Topic Discussions
Google News
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Sage Therapeutics (NASDAQ:SAGE) Reaches New 52-Week Low After Analyst Downgrade - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Reaches New 52-Week Low After Analyst Downgrade - MarketBeat
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, - GlobeNewswire
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, - GlobeNewswire
Baird cuts Sage Therapeutics target, maintains Neutral rating - Investing.com
Baird cuts Sage Therapeutics target, maintains Neutral rating - Investing.com
Sage Therapeutics hits 52-week low, trading at $9.75 - Investing.com
Sage Therapeutics hits 52-week low, trading at $9.75 - Investing.com
Sage Therapeutics and Biogen halt clinical development of SAGE-324 for essential tremor - World Pharmaceutical Frontiers
Sage Therapeutics and Biogen halt clinical development of SAGE-324 for essential tremor - World Pharmaceutical Frontiers
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
next ›
last »
×